Join
Live feed
·
NEWSReleasevia Quantisnow
Kineta Inc. logo

Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.

ByQuantisnow·Wall Street's wire, on your screen.
KA· Kineta Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KA (Kineta Inc.) and more on Quantisnow.